Regenerator Genetics, Inc “ the cutting edge of genetic and tissue engineering ”

Regenerator Genetics, Regenerator Genetics, Inc Inc

““the cutting edge of genetic and tissue the cutting edge of genetic and tissue

engineeringengineering””

Executive SummaryExecutive Summary

Regenerator Genetics, Inc is a genetic Regenerator Genetics, Inc is a genetic engineering company that intends to engineering company that intends to research, design, patent and market research, design, patent and market synthetic tissue samples related to synthetic tissue samples related to

surgical and medical niche markets. surgical and medical niche markets.

ObjectivesObjectives To create an unfounded market within field of To create an unfounded market within field of

genetic engineering with the help of leading-genetic engineering with the help of leading-edge research & development. edge research & development.

To raise $100 million in “smart money” seed To raise $100 million in “smart money” seed capital in the first half of 2008. capital in the first half of 2008.

To achieve $100 million in revenue by the year To achieve $100 million in revenue by the year 2012.2012.

To obtain grants and funding from Gates & To obtain grants and funding from Gates & Wellcome Foundation and NIH totalling $50 Wellcome Foundation and NIH totalling $50 million in 2008. million in 2008.

Acquistion by Biotech/Big Pharma, possibly by Acquistion by Biotech/Big Pharma, possibly by our potential partner Genentech, by Year 10 so our potential partner Genentech, by Year 10 so as to capture capital investment.as to capture capital investment.

MissionMission

“…“…research, design, patent and research, design, patent and market synthetic tissue samples market synthetic tissue samples related to surgical and medical niche related to surgical and medical niche markets.”markets.”

“…“…save millions of lives and save millions of lives and drastically improve the quality of life drastically improve the quality of life of burn victims all over the world.”of burn victims all over the world.”

Management TeamManagement Team The management team is the current The management team is the current

management team from Genentech, a management team from Genentech, a leading leading biotechnologybiotechnology corporationcorporation

They were specifically chosen due to their They were specifically chosen due to their related state of affairs and experience related state of affairs and experience within the biotechnology firm where we within the biotechnology firm where we truly believe that their current skill-sets truly believe that their current skill-sets and relatable industry experience will and relatable industry experience will bode well for the setup and successful bode well for the setup and successful development of Regenerator Genetics, Inc.development of Regenerator Genetics, Inc.

Board of DirectorsBoard of Directors 1. J. Craig Venter – founder and originator in 1. J. Craig Venter – founder and originator in

mapping of the mapping of the human genomehuman genome

2. Elias A. Zerhouni, M.D. – NIH Director 2. Elias A. Zerhouni, M.D. – NIH Director

3. Brook Byers of KPCB Venture Capital3. Brook Byers of KPCB Venture Capital

4. 4. James D. WatsonJames D. Watson - co-discoverers of the - co-discoverers of the structure of structure of DNADNA..

5. Andrew C. von Eschenbach - Commissioner of 5. Andrew C. von Eschenbach - Commissioner of the US FDAthe US FDA

Research Location and FacilitiesResearch Location and Facilities

10 teams of compiled of Nobel Prize-10 teams of compiled of Nobel Prize-winning winning scientistsscientists, research aides and , research aides and postdoctoral students housed within a postdoctoral students housed within a 200,000 sq ft. facility.200,000 sq ft. facility.

Located in the Bay Area in San Francisco Located in the Bay Area in San Francisco and devoted solely to genetic and tissue and devoted solely to genetic and tissue engineering research where it will be engineering research where it will be surrounded by world class biomedical surrounded by world class biomedical research universities as well as Genentech research universities as well as Genentech Inc.Inc.

Main Competitors:Main Competitors:

Johnson & Johnson 181.64BJohnson & Johnson 181.64B

Genentech, Inc. 75.29BGenentech, Inc. 75.29B

Medarex, Inc. 1.32BMedarex, Inc. 1.32B

ImClone Systems 3.67BImClone Systems 3.67B

Wyeth 56.08BWyeth 56.08B

Wyeth Wyeth

……involved with the discovery, involved with the discovery, development, manufacture, development, manufacture, distribution, and sale of distribution, and sale of pharmaceuticals, & consumer pharmaceuticals, & consumer healthcare.healthcare.

Our product is so revolutionary that it Our product is so revolutionary that it offers something that this company offers something that this company simply can’t match. simply can’t match.

Johnson and Johnson Johnson and Johnson

It manufactures and sells various products It manufactures and sells various products in the health care field worldwide.in the health care field worldwide.

It operates in three market segments: It operates in three market segments: Consumer, Pharmaceutical, and Medical Consumer, Pharmaceutical, and Medical Devices and Diagnostics.Devices and Diagnostics.

Not levered to biotech, would have Not levered to biotech, would have difficulty competing inhouse. difficulty competing inhouse.

Alliance AnalysisAlliance Analysis

Genentech, Inc engages in the discovery, Genentech, Inc engages in the discovery, development, manufacture, and development, manufacture, and commercialization of bio-therapeutics in commercialization of bio-therapeutics in the US. the US.

Similar Management TeamsSimilar Management Teams

Complementing products in biotechComplementing products in biotech

Geographical ProximityGeographical Proximity

MarketingMarketing

Focus on Doctor and Hospital Focus on Doctor and Hospital awareness and implementationawareness and implementation

First market basic products First market basic products piggyback new products as they piggyback new products as they come onlinecome online

Let media handle customer Let media handle customer awarenessawareness

Exit StrategyExit Strategy

Be acquired by large healthcare Be acquired by large healthcare company at the end of the 10 year company at the end of the 10 year investment horizoninvestment horizon

Possible sale to J&J, Wyeth, Possible sale to J&J, Wyeth, GenentechGenentech

Likely sale to Genentech if alliance is Likely sale to Genentech if alliance is achieved in early stagesachieved in early stages